RecruitingNCT06752759
Nebulized ketamine for people hospitalized with moderate to severe depression
About this title
Read the official source — NCT06752759Medication studyAges 18–88United States
Understand this study
Who could participate?
This study is for people with depression. Listed age limits: 18 years to 88 years. Other eligibility criteria apply.
- Listed locations
- BrooklynSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: October 16, 2024
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 40
- Sponsor
- Theresa Jacob, PhD, MPH
- Sponsor type
- Individual investigator
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States
- Age range
- From 18 Years to 88 Years
- Official registry ID
- NCT06752759
- Official title
Show the full official title
Nebulized Ketamine for the Treatment of Major Depressive Disorder in an Inpatient Setting: A Midazolam-controlled Randomized Controlled Trial
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Brooklyn
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Theresa Jacob, PhD, MPH.
Does this study involve medication?
Yes. The study involves medication, including nebulized ketamine and nebulized midazolam.
Who can participate?
This study is for people with depression. Listed age limits: 18 years to 88 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as recruiting.
